Drug Profile
SC 003
Alternative Names: SC-003Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Stemcentrx
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ovarian cancer; Solid tumours
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 28 Oct 2021 No recent reports of development identified for phase-I development in Ovarian-cancer(Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)